Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis

Experimental and Toxicologic Pathology

Volumn 63, Issue 6, 2011, Pages 569-574

  Aghazadeh, Safiyeh ^a   Amini, Rahim ^a   Yazdanparast, Razieh ^a   Ghaffari, Seyed H ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

JNK; Nonalcoholic steatohepatitis; Silybum marianum; TGF ; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CHOLINE; GLUTATHIONE; MALONALDEHYDE; MESSENGER RNA; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 3; SILYBUM MARIANUM EXTRACT; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOBLOTTING; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLANT SEED; RAT; SILYBUM MARIANUM; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; FATTY LIVER; LIPID PEROXIDATION; LIVER; LIVER FUNCTION TESTS; MALE; MILK THISTLE; OXIDATIVE STRESS; PLANT EXTRACTS; RATS; RATS, INBRED STRAINS; REAL-TIME POLYMERASE CHAIN REACTION; SEEDS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS; SILYBUM MARIANUM;

EID: 80051678335     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2010.04.009     Document Type: Article

References (37)

1. Aghazadeh S, Yazdanparast R. Inhibition of JNK along with activation of ERK1/2 MAPK pathways improve steatohepatitis among the rats. Clin Nutr (2009), doi:10.1016/j.clnu.2009.08.014.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
3. Bissell D.M., Roulot D., George J. Transforming growth factor beta and the liver. Hepatology 2001, 34:859-867.
4. Bugianesi E., Marzocchi R., Villanova N., Marchesini G. Non-alcoholic fatty liver/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 2004, 18:1105-1116.
5. Canbay A., Friedman S., Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
6. Copaci I., Micu L., Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A systematic review. J Gastrointestin Liver Dis 2006, 15:363-373.
7. Czaja M.J., Liu H., Wang Y. Oxidant-induced hepatocyte injury from menadione is regulated by ERK and AP-1 signaling. Hepatology 2003, 37:1405-1413.
8. Day C.P., James O.F. Steatohepatitis: a tale of two " hits" Gastroenterology 1998, 114:842-845.
9. de Zwart L.L., Meerman J.H., Commandeur J.N., Vermeulen N.P. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 1999, 26:202-226.
10. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Meth Enzymol 1990, 186:421-431.
11. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
12. Fernández-Escalante J.C., Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
13. Gold E.J., Monaghan M.A., Fleming J.S. Rat activin-βE mRNA expression during development and in acute and chronic liver injury. J Mol Genet Med 2006, 2:93-100.
14. Grattagliano I., Vendemiale G., Caraceni P., Domenicali M., Nardo B., Cavallari A., et al. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J Nutr 2000, 130:2131-2136.
15. Harrison S.A., Kadakia S., Lang K.A., Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002, 97:2714-2724.
16. Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
17. Jollow D.J., Mitchell J.R., Zampaglione N., Gillette J.R. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974, 11:151-169.
18. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
19. Kren V., Walterová D. Silybin and silymarin: new effects and applications. Biomed Pap 2005, 149:29-41.
20. Laurent A., Nicco C., Tran Van Nhieu J., Borderie D., Chéreau C., Conti F., et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 2004, 39:1277-1285.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
22. Li J.T., Liao Z.X., Ping J., Xu D., Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol 2008, 43:419-428.
23. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002, 192:1-15.
24. Nagata K., Somura F., Obata K., Odashima M., Izawa H., Ichihara S., et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002, 40:168-174.
25. Oliveira C.P., Gayotto L.C., Tatai C., Della Bina B.I., Janiszewski M., Lima E.S., et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med 2002, 6:399-406.
26. Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006, 124:491-504.
27. Ramakrishnan G., Raghavendran H.R., Vinodhkumar R., Devaki T. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem Biol Interact 2006, 161:104-114.
28. Rioja I., Clayton C.L., Graham S.J., Life P.F., Dickson M.C. Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis. Arthritis Res Ther 2005, 7:R101-117.
29. Schattenberg J.M., Singh R., Wang Y., Lefkowitch J.H., Rigoli R.M., Scherer P.E., et al. Jnk1 but not jnk2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43:163-172.
30. Sluss H.K., Barrett T., Dérijard B., Davis R.J. Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol 1994, 14:8376-8384.
31. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467-1476.
32. Ura S., Masuyama N., Graves J.D., Gotoh Y. MST1-JNK promotes apoptosis via caspase-dependent and independent pathways. Genes Cells 2001, 6:519-530.
33. Ustundag B., Bahcecioglu I.H., Sahin K., Duzgun S., Koca S., Gulcu F., et al. Protective effects of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007, 52:2006-2014.
34. Valenzuela A., Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994, 27:105-112.
35. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr Opin Cell Biol 2007, 19:142-149.
36. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
37. Yalniz M., Bahcecioglu I.H., Kuzu N., Poyrazoglu O.K., Bulmus O., Celebi S., et al. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2007, 22:2009-2014.